ID   KS6A5_HUMAN             Reviewed;         802 AA.
AC   O75582; B7Z2Y5; O95316; Q96AF7;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   15-MAR-2017, entry version 175.
DE   RecName: Full=Ribosomal protein S6 kinase alpha-5;
DE            Short=S6K-alpha-5;
DE            EC=2.7.11.1;
DE   AltName: Full=90 kDa ribosomal protein S6 kinase 5;
DE   AltName: Full=Nuclear mitogen- and stress-activated protein kinase 1;
DE   AltName: Full=RSK-like protein kinase;
DE            Short=RSKL;
GN   Name=RPS6KA5; Synonyms=MSK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAC69577.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ENZYME REGULATION,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF ASP-195
RP   AND ASP-565.
RC   TISSUE=Pancreas {ECO:0000269|PubMed:9687510};
RX   PubMed=9687510; DOI=10.1093/emboj/17.15.4426;
RA   Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.;
RT   "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly
RT   activated by MAPK and SAPK2/p38, and may mediate activation of CREB.";
RL   EMBO J. 17:4426-4441(1998).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta {ECO:0000269|PubMed:9873047};
RX   PubMed=9873047; DOI=10.1074/jbc.274.2.1026;
RA   New L., Zhao M., Li Y., Bassett W.W., Feng Y., Ludwig S., Padova F.D.,
RA   Gram H., Han J.;
RT   "Cloning and characterization of RLPK, a novel RSK-related protein
RT   kinase.";
RL   J. Biol. Chem. 274:1026-1032(1999).
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHROMOSOMAL LOCATION.
RX   PubMed=10702687;
RA   Jiang C., Yu L., Tu Q., Zhao Y., Zhang H., Zhao S.;
RT   "Assignment of a member of the ribosomal protein S6 kinase family,
RT   RPS6KA5, to human chromosome 14q31-q32.1 by radiation hybrid
RT   mapping.";
RL   Cytogenet. Cell Genet. 87:261-262(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Caudate nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta {ECO:0000312|EMBL:AAH17187.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=11909979; DOI=10.1128/MCB.22.8.2871-2881.2002;
RA   Wiggin G.R., Soloaga A., Foster J.M., Murray-Tait V., Cohen P.,
RA   Arthur J.S.;
RT   "MSK1 and MSK2 are required for the mitogen- and stress-induced
RT   phosphorylation of CREB and ATF1 in fibroblasts.";
RL   Mol. Cell. Biol. 22:2871-2881(2002).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH RELA.
RX   PubMed=12628924; DOI=10.1093/emboj/cdg139;
RA   Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W.,
RA   Haegeman G.;
RT   "Transcriptional activation of the NF-kappaB p65 subunit by mitogen-
RT   and stress-activated protein kinase-1 (MSK1).";
RL   EMBO J. 22:1313-1324(2003).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H3 AND HMGN1/HMG14.
RX   PubMed=12773393; DOI=10.1093/emboj/cdg273;
RA   Soloaga A., Thomson S., Wiggin G.R., Rampersaud N., Dyson M.H.,
RA   Hazzalin C.A., Mahadevan L.C., Arthur J.S.;
RT   "MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation
RT   of histone H3 and HMG-14.";
RL   EMBO J. 22:2788-2797(2003).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF STAT3.
RX   PubMed=12763138; DOI=10.1016/S0301-472X(03)00045-6;
RA   Wierenga A.T., Vogelzang I., Eggen B.J., Vellenga E.;
RT   "Erythropoietin-induced serine 727 phosphorylation of STAT3 in
RT   erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent
RT   pathway.";
RL   Exp. Hematol. 31:398-405(2003).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF ETV1/ER81, AND INTERACTION WITH CREBBP
RP   AND EP300.
RX   PubMed=12569367; DOI=10.1038/sj.onc.1206185;
RA   Janknecht R.;
RT   "Regulation of the ER81 transcription factor and its coactivators by
RT   mitogen- and stress-activated protein kinase 1 (MSK1).";
RL   Oncogene 22:746-755(2003).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF HISTONE H2A.
RX   PubMed=15010469; DOI=10.1074/jbc.M400099200;
RA   Zhang Y., Griffin K., Mondal N., Parvin J.D.;
RT   "Phosphorylation of histone H2A inhibits transcription on chromatin
RT   templates.";
RL   J. Biol. Chem. 279:21866-21872(2004).
RN   [13]
RP   ENZYME REGULATION, PHOSPHORYLATION AT SER-212; SER-360; SER-376;
RP   SER-381; THR-581; SER-750; SER-752 AND SER-758, AND MUTAGENESIS OF
RP   SER-212; SER-360; SER-376 AND THR-581.
RX   PubMed=15568999; DOI=10.1042/BJ20041501;
RA   McCoy C.E., Campbell D.G., Deak M., Bloomberg G.B., Arthur J.S.C.;
RT   "MSK1 activity is controlled by multiple phosphorylation sites.";
RL   Biochem. J. 387:507-517(2005).
RN   [14]
RP   PHOSPHORYLATION AT SER-647; SER-657; SER-695 AND THR-700, AND
RP   MUTAGENESIS OF THR-700.
RX   PubMed=17117922; DOI=10.1042/BJ20061183;
RA   McCoy C.E., Macdonald A., Morrice N.A., Campbell D.G., Deak M.,
RA   Toth R., McIlrath J., Arthur J.S.;
RT   "Identification of novel phosphorylation sites in MSK1 by precursor
RT   ion scanning MS.";
RL   Biochem. J. 402:491-501(2007).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18511904; DOI=10.1038/emboj.2008.95;
RA   Beck I.M., Vanden Berghe W., Vermeulen L., Bougarne N.,
RA   Vander Cruyssen B., Haegeman G., De Bosscher K.;
RT   "Altered subcellular distribution of MSK1 induced by glucocorticoids
RT   contributes to NF-kappaB inhibition.";
RL   EMBO J. 27:1682-1693(2008).
RN   [16]
RP   REVIEW ON FUNCTION.
RX   PubMed=18508628; DOI=10.2741/3122;
RA   Arthur J.S.;
RT   "MSK activation and physiological roles.";
RL   Front. Biosci. 13:5866-5879(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-376, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=19464896; DOI=10.1016/j.tibs.2009.02.007;
RA   Vermeulen L., Vanden Berghe W., Beck I.M., De Bosscher K.,
RA   Haegeman G.;
RT   "The versatile role of MSKs in transcriptional regulation.";
RL   Trends Biochem. Sci. 34:311-318(2009).
RN   [19]
RP   UBIQUITINATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-
RT   translational modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-376 AND SER-381, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 2-348.
RX   PubMed=15274926; DOI=10.1016/j.str.2004.02.040;
RA   Smith K.J., Carter P.S., Bridges A., Horrocks P., Lewis C.,
RA   Pettman G., Clarke A., Brown M., Hughes J., Wilkinson M., Bax B.,
RA   Reith A.;
RT   "The structure of MSK1 reveals a novel autoinhibitory conformation for
RT   a dual kinase protein.";
RL   Structure 12:1067-1077(2004).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 414-738.
RX   PubMed=20382163; DOI=10.1016/j.jmb.2010.03.064;
RA   Malakhova M., D'Angelo I., Kim H.G., Kurinov I., Bode A.M., Dong Z.;
RT   "The crystal structure of the active form of the C-terminal kinase
RT   domain of mitogen- and stress-activated protein kinase 1.";
RL   J. Mol. Biol. 399:41-52(2010).
RN   [24]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-554; LEU-574 AND CYS-599.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that is required for the
CC       mitogen or stress-induced phosphorylation of the transcription
CC       factors CREB1 and ATF1 and for the regulation of the transcription
CC       factors RELA, STAT3 and ETV1/ER81, and that contributes to gene
CC       activation by histone phosphorylation and functions in the
CC       regulation of inflammatory genes. Phosphorylates CREB1 and ATF1 in
CC       response to mitogenic or stress stimuli such as UV-C irradiation,
CC       epidermal growth factor (EGF) and anisomycin. Plays an essential
CC       role in the control of RELA transcriptional activity in response
CC       to TNF and upon glucocorticoid, associates in the cytoplasm with
CC       the glucocorticoid receptor NR3C1 and contributes to RELA
CC       inhibition and repression of inflammatory gene expression. In
CC       skeletal myoblasts is required for phosphorylation of RELA at
CC       'Ser-276' during oxidative stress. In erythropoietin-stimulated
CC       cells, is necessary for the 'Ser-727' phosphorylation of STAT3 and
CC       regulation of its transcriptional potential. Phosphorylates
CC       ETV1/ER81 at 'Ser-191' and 'Ser-216', and thereby regulates its
CC       ability to stimulate transcription, which may be important during
CC       development and breast tumor formation. Directly represses
CC       transcription via phosphorylation of 'Ser-1' of histone H2A.
CC       Phosphorylates 'Ser-10' of histone H3 in response to mitogenics,
CC       stress stimuli and EGF, which results in the transcriptional
CC       activation of several immediate early genes, including proto-
CC       oncogenes c-fos/FOS and c-jun/JUN. May also phosphorylate 'Ser-28'
CC       of histone H3. Mediates the mitogen- and stress-induced
CC       phosphorylation of high mobility group protein 1 (HMGN1/HMG14). In
CC       lipopolysaccharide-stimulated primary macrophages, acts downstream
CC       of the Toll-like receptor TLR4 to limit the production of pro-
CC       inflammatory cytokines. Functions probably by inducing
CC       transcription of the MAP kinase phosphatase DUSP1 and the anti-
CC       inflammatory cytokine interleukin 10 (IL10), via CREB1 and ATF1
CC       transcription factors. Plays a role in neuronal cell death by
CC       mediating the downstream effects of excitotoxic injury.
CC       {ECO:0000269|PubMed:11909979, ECO:0000269|PubMed:12569367,
CC       ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:12763138,
CC       ECO:0000269|PubMed:12773393, ECO:0000269|PubMed:15010469,
CC       ECO:0000269|PubMed:18511904, ECO:0000269|PubMed:9687510,
CC       ECO:0000269|PubMed:9873047}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:12628924, ECO:0000269|PubMed:9687510,
CC       ECO:0000269|PubMed:9873047}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:12628924,
CC         ECO:0000269|PubMed:9687510, ECO:0000269|PubMed:9873047};
CC   -!- ENZYME REGULATION: Activated by phosphorylation at Ser-360, Thr-
CC       581 and Thr-700 by MAPK1/ERK2, MAPK3/ERK1 and MAPK14/p38-alpha,
CC       and by further autophosphorylation of Ser-212, Ser-376 and Ser-381
CC       by the activated C-terminal kinase domain. The active N-terminal
CC       kinase domain finally phosphorylates downstream substrates, as
CC       well as Ser-750, Ser-752 and Ser-758 in its own C-terminal region.
CC       {ECO:0000269|PubMed:15568999, ECO:0000269|PubMed:9687510}.
CC   -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in
CC       quiescent cells which transiently dissociates following mitogenic
CC       stimulation. Also associates with MAPK14/p38-alpha. Activated
CC       RPS6KA5 associates with and phosphorylates the NF-kappa-B p65
CC       subunit RELA. Interacts with CREBBP and EP300.
CC       {ECO:0000269|PubMed:12569367, ECO:0000269|PubMed:12628924}.
CC   -!- INTERACTION:
CC       Q04206:RELA; NbExp=2; IntAct=EBI-73869, EBI-73886;
CC       Q9NYL2:ZAK; NbExp=4; IntAct=EBI-73869, EBI-602273;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Predominantly
CC       nuclear. Exported into cytoplasm in response to glucocorticoid.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O75582-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75582-2; Sequence=VSP_041837, VSP_041838;
CC       Name=3;
CC         IsoId=O75582-3; Sequence=VSP_057410;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed with high levels in heart,
CC       brain and placenta. Less abundant in lung, kidney and liver.
CC       {ECO:0000269|PubMed:9687510, ECO:0000269|PubMed:9873047}.
CC   -!- PTM: Ser-376 and Thr-581 phosphorylation is required for kinase
CC       activity. Ser-376 and Ser-212 are autophosphorylated by the C-
CC       terminal kinase domain, and their phosphorylation is essential for
CC       the catalytic activity of the N-terminal kinase domain.
CC       Phosphorylated at Ser-360, Thr-581 and Thr-700 by MAPK1/ERK2,
CC       MAPK3/ERK1 and MAPK14/p38-alpha. Autophosphorylated at Ser-750,
CC       Ser-752 and Ser-758 by the N-terminal kinase domain.
CC       {ECO:0000269|PubMed:15568999, ECO:0000269|PubMed:17117922}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}.
CC   -!- MISCELLANEOUS: Enzyme activity requires the presence of both
CC       kinase domains. {ECO:0000269|PubMed:9687510}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC69577.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF074393; AAC31171.1; -; mRNA.
DR   EMBL; AF080000; AAD23915.1; -; mRNA.
DR   EMBL; AF090421; AAC69577.1; ALT_FRAME; mRNA.
DR   EMBL; AK295266; BAH12021.1; -; mRNA.
DR   EMBL; AL121784; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133454; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL159191; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017187; AAH17187.1; -; mRNA.
DR   CCDS; CCDS45149.1; -. [O75582-2]
DR   CCDS; CCDS81839.1; -. [O75582-3]
DR   CCDS; CCDS9893.1; -. [O75582-1]
DR   PIR; T13149; T13149.
DR   RefSeq; NP_001309164.1; NM_001322235.1. [O75582-3]
DR   RefSeq; NP_001309166.1; NM_001322237.1. [O75582-3]
DR   RefSeq; NP_004746.2; NM_004755.3. [O75582-1]
DR   RefSeq; NP_872198.1; NM_182398.2. [O75582-2]
DR   UniGene; Hs.510225; -.
DR   PDB; 1VZO; X-ray; 1.80 A; A=2-348.
DR   PDB; 3KN5; X-ray; 2.40 A; A/B=414-738.
DR   PDB; 3KN6; X-ray; 2.00 A; A/B=414-738.
DR   PDBsum; 1VZO; -.
DR   PDBsum; 3KN5; -.
DR   PDBsum; 3KN6; -.
DR   ProteinModelPortal; O75582; -.
DR   SMR; O75582; -.
DR   BioGrid; 114676; 53.
DR   DIP; DIP-30894N; -.
DR   IntAct; O75582; 36.
DR   MINT; MINT-261060; -.
DR   STRING; 9606.ENSP00000261991; -.
DR   BindingDB; O75582; -.
DR   ChEMBL; CHEMBL4237; -.
DR   GuidetoPHARMACOLOGY; 1523; -.
DR   iPTMnet; O75582; -.
DR   PhosphoSitePlus; O75582; -.
DR   BioMuta; RPS6KA5; -.
DR   EPD; O75582; -.
DR   MaxQB; O75582; -.
DR   PaxDb; O75582; -.
DR   PeptideAtlas; O75582; -.
DR   PRIDE; O75582; -.
DR   DNASU; 9252; -.
DR   Ensembl; ENST00000418736; ENSP00000402787; ENSG00000100784. [O75582-2]
DR   Ensembl; ENST00000536315; ENSP00000442803; ENSG00000100784. [O75582-3]
DR   Ensembl; ENST00000614987; ENSP00000479667; ENSG00000100784. [O75582-1]
DR   GeneID; 9252; -.
DR   KEGG; hsa:9252; -.
DR   UCSC; uc001xys.4; human. [O75582-1]
DR   UCSC; uc010twi.3; human.
DR   CTD; 9252; -.
DR   DisGeNET; 9252; -.
DR   GeneCards; RPS6KA5; -.
DR   HGNC; HGNC:10434; RPS6KA5.
DR   HPA; CAB025458; -.
DR   HPA; HPA001274; -.
DR   HPA; HPA001780; -.
DR   MIM; 603607; gene.
DR   neXtProt; NX_O75582; -.
DR   OpenTargets; ENSG00000100784; -.
DR   PharmGKB; PA34849; -.
DR   eggNOG; KOG0598; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00860000133668; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; O75582; -.
DR   KO; K04445; -.
DR   PhylomeDB; O75582; -.
DR   TreeFam; TF313438; -.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-199920; CREB phosphorylation.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   SABIO-RK; O75582; -.
DR   SignaLink; O75582; -.
DR   SIGNOR; O75582; -.
DR   ChiTaRS; RPS6KA5; human.
DR   EvolutionaryTrace; O75582; -.
DR   GeneWiki; RPS6KA5; -.
DR   GenomeRNAi; 9252; -.
DR   PRO; PR:O75582; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000100784; -.
DR   CleanEx; HS_RPS6KA5; -.
DR   ExpressionAtlas; O75582; baseline and differential.
DR   Genevisible; O75582; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0043990; P:histone H2A-S1 phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043987; P:histone H3-S10 phosphorylation; IMP:UniProtKB.
DR   GO; GO:0043988; P:histone H3-S28 phosphorylation; IMP:UniProtKB.
DR   GO; GO:0016572; P:histone phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0001818; P:negative regulation of cytokine production; TAS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; IMP:BHF-UCL.
DR   GO; GO:0033129; P:positive regulation of histone phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016239; Ribosomal_S6_kinase_II.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 2.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Inflammatory response; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Stress response; Transferase; Ubl conjugation.
FT   CHAIN         1    802       Ribosomal protein S6 kinase alpha-5.
FT                                /FTId=PRO_0000086207.
FT   DOMAIN       49    318       Protein kinase 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      319    387       AGC-kinase C-terminal.
FT   DOMAIN      426    687       Protein kinase 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      55     63       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     432    440       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    177    177       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    544    544       Proton acceptor. {ECO:0000250}.
FT   BINDING      81     81       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     455    455       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     212    212       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15568999}.
FT   MOD_RES     360    360       Phosphoserine; by MAPK1, MAPK3 and
FT                                MAPK14. {ECO:0000269|PubMed:15568999}.
FT   MOD_RES     376    376       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000269|PubMed:15568999}.
FT   MOD_RES     381    381       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000269|PubMed:15568999}.
FT   MOD_RES     581    581       Phosphothreonine; by MAPK1, MAPK3 and
FT                                MAPK14. {ECO:0000269|PubMed:15568999}.
FT   MOD_RES     647    647       Phosphoserine.
FT                                {ECO:0000269|PubMed:17117922}.
FT   MOD_RES     657    657       Phosphoserine.
FT                                {ECO:0000269|PubMed:17117922}.
FT   MOD_RES     691    691       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8C050}.
FT   MOD_RES     695    695       Phosphoserine.
FT                                {ECO:0000269|PubMed:17117922}.
FT   MOD_RES     700    700       Phosphothreonine; by MAPK1, MAPK3 and
FT                                MAPK14. {ECO:0000269|PubMed:17117922}.
FT   MOD_RES     750    750       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15568999}.
FT   MOD_RES     752    752       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15568999}.
FT   MOD_RES     758    758       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15568999}.
FT   MOD_RES     798    798       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8C050}.
FT   VAR_SEQ       1     79       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057410.
FT   VAR_SEQ     549    549       N -> V (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041837.
FT   VAR_SEQ     550    802       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041838.
FT   VARIANT     190    190       H -> R (in dbSNP:rs34699345).
FT                                /FTId=VAR_051634.
FT   VARIANT     554    554       D -> N (in dbSNP:rs55911249).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040634.
FT   VARIANT     574    574       P -> L (in dbSNP:rs34604933).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040635.
FT   VARIANT     599    599       Y -> C (in dbSNP:rs55968863).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040636.
FT   MUTAGEN     195    195       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:9687510}.
FT   MUTAGEN     212    212       S->A: Inactivates the N-terminal kinase
FT                                domain. {ECO:0000269|PubMed:15568999}.
FT   MUTAGEN     360    360       S->A: Decreases kinase activity by 60% in
FT                                response to PMA and UV-C.
FT                                {ECO:0000269|PubMed:15568999}.
FT   MUTAGEN     376    376       S->A: Loss of kinase activity, and
FT                                decreases the phosphorylation of S-360
FT                                and T-581. {ECO:0000269|PubMed:15568999}.
FT   MUTAGEN     565    565       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:9687510}.
FT   MUTAGEN     581    581       T->A: Loss of kinase activity, and blocks
FT                                phosphorylation of S-212; S-376 and S-381
FT                                in response to PMA and UV-C.
FT                                {ECO:0000269|PubMed:15568999}.
FT   MUTAGEN     700    700       T->A,D: Strongly reduces phosphorylation
FT                                of T-581 in response to PMA and UV-C.
FT                                {ECO:0000269|PubMed:17117922}.
FT   CONFLICT    452    453       FA -> LQ (in Ref. 3; AAC69577).
FT                                {ECO:0000305}.
FT   CONFLICT    532    532       V -> L (in Ref. 3; AAC69577).
FT                                {ECO:0000305}.
FT   CONFLICT    538    538       V -> L (in Ref. 3; AAC69577).
FT                                {ECO:0000305}.
FT   CONFLICT    757    758       SS -> RG (in Ref. 3; AAC69577).
FT                                {ECO:0000305}.
FT   STRAND       26     31       {ECO:0000244|PDB:1VZO}.
FT   HELIX        46     48       {ECO:0000244|PDB:1VZO}.
FT   STRAND       49     57       {ECO:0000244|PDB:1VZO}.
FT   TURN         58     60       {ECO:0000244|PDB:1VZO}.
FT   STRAND       61     68       {ECO:0000244|PDB:1VZO}.
FT   TURN         72     75       {ECO:0000244|PDB:1VZO}.
FT   STRAND       77     94       {ECO:0000244|PDB:1VZO}.
FT   HELIX        95     97       {ECO:0000244|PDB:1VZO}.
FT   HELIX       101    109       {ECO:0000244|PDB:1VZO}.
FT   STRAND      117    123       {ECO:0000244|PDB:1VZO}.
FT   STRAND      126    131       {ECO:0000244|PDB:1VZO}.
FT   HELIX       139    146       {ECO:0000244|PDB:1VZO}.
FT   HELIX       151    170       {ECO:0000244|PDB:1VZO}.
FT   HELIX       180    182       {ECO:0000244|PDB:1VZO}.
FT   STRAND      183    185       {ECO:0000244|PDB:1VZO}.
FT   STRAND      191    194       {ECO:0000244|PDB:1VZO}.
FT   STRAND      196    201       {ECO:0000244|PDB:1VZO}.
FT   HELIX       204    210       {ECO:0000244|PDB:1VZO}.
FT   HELIX       222    225       {ECO:0000244|PDB:1VZO}.
FT   HELIX       235    250       {ECO:0000244|PDB:1VZO}.
FT   HELIX       264    273       {ECO:0000244|PDB:1VZO}.
FT   HELIX       284    293       {ECO:0000244|PDB:1VZO}.
FT   HELIX       298    300       {ECO:0000244|PDB:1VZO}.
FT   TURN        306    308       {ECO:0000244|PDB:1VZO}.
FT   HELIX       309    313       {ECO:0000244|PDB:1VZO}.
FT   HELIX       316    318       {ECO:0000244|PDB:1VZO}.
FT   HELIX       323    327       {ECO:0000244|PDB:1VZO}.
FT   HELIX       418    422       {ECO:0000244|PDB:3KN6}.
FT   STRAND      423    425       {ECO:0000244|PDB:3KN6}.
FT   STRAND      432    435       {ECO:0000244|PDB:3KN6}.
FT   STRAND      438    445       {ECO:0000244|PDB:3KN6}.
FT   TURN        446    448       {ECO:0000244|PDB:3KN6}.
FT   STRAND      451    458       {ECO:0000244|PDB:3KN6}.
FT   HELIX       459    461       {ECO:0000244|PDB:3KN6}.
FT   HELIX       462    474       {ECO:0000244|PDB:3KN6}.
FT   TURN        475    477       {ECO:0000244|PDB:3KN6}.
FT   STRAND      484    489       {ECO:0000244|PDB:3KN6}.
FT   STRAND      491    498       {ECO:0000244|PDB:3KN6}.
FT   HELIX       506    512       {ECO:0000244|PDB:3KN6}.
FT   HELIX       518    537       {ECO:0000244|PDB:3KN6}.
FT   HELIX       547    549       {ECO:0000244|PDB:3KN6}.
FT   STRAND      550    553       {ECO:0000244|PDB:3KN6}.
FT   STRAND      560    563       {ECO:0000244|PDB:3KN6}.
FT   HELIX       602    617       {ECO:0000244|PDB:3KN6}.
FT   HELIX       634    641       {ECO:0000244|PDB:3KN6}.
FT   TURN        642    644       {ECO:0000244|PDB:3KN6}.
FT   HELIX       651    654       {ECO:0000244|PDB:3KN6}.
FT   HELIX       658    668       {ECO:0000244|PDB:3KN6}.
FT   TURN        672    674       {ECO:0000244|PDB:3KN6}.
FT   TURN        678    680       {ECO:0000244|PDB:3KN6}.
FT   HELIX       685    687       {ECO:0000244|PDB:3KN6}.
FT   HELIX       700    728       {ECO:0000244|PDB:3KN6}.
SQ   SEQUENCE   802 AA;  89865 MW;  76C27D0F6639BFA4 CRC64;
     MEEEGGSSGG AAGTSADGGD GGEQLLTVKH ELRTANLTGH AEKVGIENFE LLKVLGTGAY
     GKVFLVRKIS GHDTGKLYAM KVLKKATIVQ KAKTTEHTRT ERQVLEHIRQ SPFLVTLHYA
     FQTETKLHLI LDYINGGELF THLSQRERFT EHEVQIYVGE IVLALEHLHK LGIIYRDIKL
     ENILLDSNGH VVLTDFGLSK EFVADETERA YSFCGTIEYM APDIVRGGDS GHDKAVDWWS
     LGVLMYELLT GASPFTVDGE KNSQAEISRR ILKSEPPYPQ EMSALAKDLI QRLLMKDPKK
     RLGCGPRDAD EIKEHLFFQK INWDDLAAKK VPAPFKPVIR DELDVSNFAE EFTEMDPTYS
     PAALPQSSEK LFQGYSFVAP SILFKRNAAV IDPLQFHMGV ERPGVTNVAR SAMMKDSPFY
     QHYDLDLKDK PLGEGSFSIC RKCVHKKSNQ AFAVKIISKR MEANTQKEIT ALKLCEGHPN
     IVKLHEVFHD QLHTFLVMEL LNGGELFERI KKKKHFSETE ASYIMRKLVS AVSHMHDVGV
     VHRDLKPENL LFTDENDNLE IKIIDFGFAR LKPPDNQPLK TPCFTLHYAA PELLNQNGYD
     ESCDLWSLGV ILYTMLSGQV PFQSHDRSLT CTSAVEIMKK IKKGDFSFEG EAWKNVSQEA
     KDLIQGLLTV DPNKRLKMSG LRYNEWLQDG SQLSSNPLMT PDILGSSGAA VHTCVKATFH
     AFNKYKREGF CLQNVDKAPL AKRRKMKKTS TSTETRSSSS ESSHSSSSHS HGKTTPTKTL
     QPSNPADSNN PETLFQFSDS VA
//
